Experience

Davis Polk advised the underwriters in connection with an initial public offering of 8,047,227 American Depositary Shares of Innate Pharma S.A. and a concurrent private placement of 4,452…

Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American Depositary Shares of BioNTech SE. In addition, the underwriters have…

Davis Polk advised the joint book-running managers in connection with an offering by Beazer Homes USA, Inc. of $350 million aggregate principal amount of its 7.250% notes due 2029. Davis…

Davis Polk advised the underwriter in connection with the SEC-registered offering by PTC Therapeutics, Inc. of 2,475,248 shares of its common stock and the initial purchaser in a concurrent…

Davis Polk advised Murphy USA Inc. in connection with an SEC-registered offering of $500 million aggregate principal amount of 4.750% senior notes due 2029 and a tender offer for any and…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $800 million principal amount of 0.375% convertible senior notes due 2026,…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by PTC Therapeutics, Inc. of its shares of common stock for up to an aggregate amount of $125…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering of $1 billion aggregate principal amount of 6.750% senior notes due 2024…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Energizer Holdings, Inc. of $600 million aggregate principal amount…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering of 4,687,498 shares of common stock, including 611,412 shares of common stock…